Articles tagged with Alzheimer Disease
Research reveals that individuals with Alzheimer's disease who die from the condition itself tend to have less hospitalization and ICU stays compared to those who die from other causes. This contrasts with those who receive fewer palliative care services during their final months.
Researchers developed a high-resolution nanometer-scale magnetic resonance imaging (MRI) technique, enabling unprecedented views of biological systems. The new method extends traditional MRI capabilities to the nanoscale, providing insights into Parkinson's and Alzheimer's diseases.
Researchers used fMRI to study brain activity while watching Memento, finding repeating patterns in the brain that correspond to key scenes. These 'neural fingerprints' help viewers piece together the storyline, revealing insights into how the brain processes narratives and memory.
A new data analysis of 51 existing studies in mice reveals that phosphorylated tau (p-tau) is a more likely culprit in Alzheimer's disease than previously thought. The study also found that multiple biochemical actors work together to tear down neurons, and that soluble amyloid-beta has a strong correlation with cognitive decline.
A new study published in Neurology suggests that individuals who do not recognize their own memory problems are nearly threefold more likely to develop dementia within two years. This lack of awareness is associated with impaired brain metabolic function and higher rates of amyloid deposition, a protein linked to Alzheimer's disease.
In a groundbreaking study, researchers from the Cleveland Clinic Lerner Research Institute successfully reversed the formation of amyloid plaques in mice with Alzheimer's disease by gradually depleting the enzyme BACE1. This approach improved cognitive function and had significant benefits for the animals' health.
Pimavanserin has been found to effectively reduce psychosis symptoms in people with Alzheimer's disease without the damaging effects of other antipsychotics. The research, published in Lancet Neurology, shows a significant improvement in psychotic symptoms without sedation or falls, which are common side-effects of current treatments.
GlycoNet researchers Matthew Macauley and John Klassen are developing a strategy to identify the molecular identity of sugars interacting with CD33 protein, strongly implicated in Alzheimer's disease. This approach may lead to therapeutic targets or diagnostic tools for preventing or treating the disease.
A new study challenges the long-held assumption that amyloid beta buildup in brain cells is the origin of Alzheimer's disease. Researchers found that standard diagnostic tools fail to detect future AD in many patients under age 70, and that a decline in cerebrospinal fluid clearance may be the early feature of AD.
A new study suggests an association between overactive and cytosolic BRCA1 and neurons death in Alzheimer's disease, linked to aberrant DNA damage response and presenilin 1 dysfunction. The findings support the hypothesis that genotoxic stress manifests in neuronal death.
A new study by Concordia professor Natalie Phillips explores the effects of bilingualism on patients with Alzheimer's disease and mild cognitive impairment. The research found that multilingual individuals may be able to compensate for AD-related tissue loss by accessing alternative networks in their brains for memory processing.
NAD+ supplementation improves cognitive function, reduces DNA damage and neuroinflammation in AD mouse model with DNA repair deficiency. Researchers report promising results with potential implications for Alzheimer's disease treatment.
USC researchers found that nearly 50% of dementias begin with damaged gatekeeper cells, leading to small vessel disease and white matter disease. Controlling fibrinogen levels may reverse or slow white matter disease in a mouse model.
A new study published in Scientific Reports suggests that low doses of alcohol may be beneficial for brain health, reducing inflammation and improving the brain's ability to remove waste. This finding adds to growing research linking lower levels of drinking with a reduced risk of cardiovascular diseases and certain cancers.
The blood test measures a specific peptide to inform scientists of Alzheimer's disease presence with 90% accuracy. It has the potential to accelerate therapeutic strategies development by speeding up patient selection for new drug trials.
Researchers at Ohio State University Wexner Medical Center conducted a study on a brain pacemaker to slow the decline of problem-solving and decision-making skills in patients with Alzheimer's disease. The deep brain stimulation (DBS) implant improved cognitive, behavioral, and functional abilities in patients.
A new study reveals that people with preclinical Alzheimer's disease experience significant disruptions in their internal body clocks, even after controlling for other factors. These circadian rhythm disruptions are linked to increased risk of developing the disorder and may serve as a biomarker for early detection.
Arizona State University is developing a biomanufacturing platform to generate human neurons for testing treatments of neurodegenerative diseases. The project aims to engineer neural cell types needed for drug screening, potentially leading to innovative solutions for Alzheimer's, Parkinson's and Amyotrophic lateral sclerosis.
A new study by UCLA researchers found that daily consumption of curcumin improved memory and mood in people with mild, age-related memory loss. The study, which involved 40 adults aged 50-90, showed significant improvements in cognitive power and reduced amyloid and tau signals in the brain.
Researchers found that early personality changes can lead to noticeable behavior problems, including depression and anxiety. The study suggests that diagnosing these early changes could help develop earlier treatments for Alzheimer's disease.
A recent study published in Scientific Reports challenges the scientific consensus on Alzheimer's disease, suggesting that neuronal loss is relatively limited. The research found minor declines in synaptic markers in patients' prefrontal cortices, which had little impact on cognitive skills.
A new study suggests an association between elevated amyloid beta levels and worsening anxiety symptoms in cognitively normal older adults. Higher brain amyloid beta burden is linked to increasing anxiety symptoms over time.
Case Western Reserve University researchers have received a $2.8 million grant to identify FDA-approved medications that can be repurposed to treat Alzheimer's disease. The project aims to develop computer algorithms and test promising drug candidates using patient electronic health records and animal models.
A six-month treatment with idalopirdine failed to slow cognitive decline in patients with mild to moderate Alzheimer's disease. The study involved over 2,500 participants and used a combination of idalopirdine and cholinesterase inhibitors.
Researchers discover J147, an Alzheimer's treatment that reverses aging by targeting ATP synthase, a protein found in mitochondria. The compound has shown promising results in treating Alzheimer's and potentially other age-associated diseases.
Researchers analyze brain slices from patients with Alzheimer's and cerebral amyloid angiopathy, finding distinct amyloid-beta prion strains associated with different disease types. Mutant amyloid-beta adopts self-propagating prion structure, imparting pathological conformation to normal amyloid-beta.
Researchers are using a unique imaging technique, Quest MRI, to study the earliest signs of Alzheimer's disease in mice. The technique measures oxidative stress in specific brain regions over time and has shown promise as a potential biomarker for AD.
Researchers at Hong Kong Baptist University have invented multifunctional cyanine compounds that can be used for detection, imaging and treatment of Alzheimer's disease. The discovery has been granted US patents and a Chinese patent.
A study published in the journal Brain uses a combination of imaging techniques to examine tau build-up in patients with Alzheimer's disease and progressive supranuclear palsy. The findings support the transneuronal spread hypothesis, suggesting that tau starts in one place and spreads throughout the brain.
Researchers have identified several genes responsible for Alzheimer's disease, including those affecting brain structure and function. These findings provide insight into the biological mechanisms leading to AD, particularly in the pre-symptom stages, and may lead to new treatments.
Pericytes, a type of cell on brain blood vessels, grow to cover empty space left by neighboring cells. This brain plasticity may help fight age-related vascular disorders like Alzheimer's disease and stroke.
A diabetes drug has been found to significantly reverse memory loss in mice with Alzheimer's disease through a triple method of action. The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer's disease.
A new guideline from Mayo Clinic suggests that exercise can help people with mild cognitive impairment, which is an intermediate stage between normal aging and dementia. Twice-weekly workouts of 30 minutes or less may slow down the progression of symptoms.
A new study reveals that inflammatory mechanisms in the brain drive Alzheimer's disease progression. The research found a molecular complex of the immune system promotes aberrant aggregation of proteins, including Amyloid-beta, which accumulates in the brain and harms neurons.
Researchers have linked changes in brain anatomy to early biomarkers of Alzheimer's disease, suggesting a non-invasive test may detect AD before symptoms appear. The study found that specific regions of the hippocampal circuit shrink in individuals with high levels of tau and amyloid-Beta proteins.
The compound anle138b was shown to close harmful openings in the membrane of nerve cells and induce conformational changes that modify pore conductivity. Treatment with anle138b normalized brain activity and improved learning ability in mice affected by Alzheimer's disease, regardless of when treatment started.
Two new studies will investigate evidence-based decision aids for Alzheimer's disease care and a comprehensive collaborative care program for veterans with TBI or AD and their caregivers. The programs aim to improve quality of life, reduce burden and depression among caregivers.
Researchers at Tel Aviv University have identified a novel form of protein aggregation that is both reversible and has positive physiological consequences for cells. This discovery may lead to new treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's.
A large-scale genetic study has clarified the distinctive genetic signature of Dementia with Lewy bodies, a common type of dementia. The research found that DLB accounts for 10-15% of dementia cases, but its genetic profile is unique compared to Alzheimer's and Parkinson's diseases.
Researchers are investigating genetic variations that offer protection against Alzheimer's disease in elderly Amish individuals. They will also explore the causes of rapidly progressing late-onset Alzheimer's disease, which is characterized by a faster rate of cognitive decline and death compared to typical cases.
The National Institutes of Health is awarding up to $70 million to launch the Alzheimer's Clinical Trials Consortium, a network of 35 trial sites aiming to find new treatments for Alzheimer's disease. The consortium will improve recruitment strategies and infrastructure to accelerate clinical trials.
A new consortium aims to accelerate clinical trials and find new treatments for Alzheimer's disease by implementing efficient participant recruitment methods. The collaboration will provide centralized services, enabling researchers to run innovative clinical trials, manage data, and recruit participants from diverse backgrounds.
A study by Temple University researchers found that mice fed canola oil daily suffered impaired working memory and increased amyloid plaques, indicative of neuronal damage. The findings suggest that long-term consumption of canola oil may be detrimental to brain health.
A new UCLA study estimates that 47 million Americans already show signs of susceptibility to Alzheimer's disease and this number is expected to double by 2060. By then, about 5.7 million will have mild cognitive impairment and 9.3 million will have dementia due to Alzheimer's.
Researchers identified a compound targeting APOE protein in mouse brains, reducing amyloid beta plaques and neurological damage. The findings suggest APOE could be a potential target for treatment or prevention of Alzheimer's disease.
A new PET tracer has been developed to effectively gauge the effectiveness of promising Alzheimer's treatments in mouse models. The tracer binds to BACE1, a key enzyme involved in amyloid-β development, and accurately measures its effects on brain metabolism, neuroinflammation, and amyloid-β pathology.
A new genetics study from the University of Cambridge has found a strong association between higher educational attainment and reduced risk of Alzheimer's disease. The study suggests that education may help build cognitive reserve, allowing individuals to better compensate for age-related brain damage.
Researchers discovered that enhancing mitochondrial defenses can reduce amyloid plaque formation and improve cognitive function in Alzheimer's disease. The approach targets the mitochondrial unfolded protein response and mitophagy mechanisms to restore cellular energy production and protect against neurodegeneration.
A new study reveals that hyperbaric oxygen therapy may correct behavioral and physical deficits associated with Alzheimer's disease. The treatment reduced plaque pathology by 40% and neuroinflammation by about 40%, improving the condition of mice with the disease.
Researchers created an animal model that closely replicates the human form of Alzheimer's disease, including pathological tau protein and amyloid plaques. This breakthrough allows for testing of new therapies targeting both pathologies.
A new tool, QuoCo, tracks cognitive performance in adults, allowing physicians to identify potential Alzheimer's patients. The tool uses age, education, and Mini-Mental State Examination scores to plot cognitive performance over time.
A team of researchers at Brigham Young University has identified a specific gene variant that protects people with high-risk genetic factors from developing Alzheimer's disease. The study reveals that this genetic function could be targeted with drugs to reduce the risk of Alzheimer's.
The full results from the second Phase 3 clinical study of LMTX confirm its efficacy as a monotherapy for mild to moderate Alzheimer's disease. The study showed significant slowing of brain atrophy and functional decline in patients treated with LMTX, while those receiving add-on therapy experienced no significant change.
A new study published in International Journal of Geriatric Psychiatry found that benzodiazepine use is associated with a 40% increased risk of death among persons with Alzheimer's disease. The study, which included over 10,380 participants, suggests that these drugs may contribute to adverse events such as falls, pneumonia, and stroke.
A unique model for Alzheimer's disease has been developed, suggesting a new approach for treating the condition. By reducing stress granule proteins, nerve cell health and memory can be improved.
Researchers found that astrocytes in AD patients produced more beta-amyloid and cytokines, leading to brain inflammation and weakened neurons. Astrocyte function alterations may play a key role in early AD stages and neurodegeneration.
A study published in Stem Cell Reports reveals that DNA-encoded factors influence the vulnerability of brain cells to Alzheimer's disease. Brain regions with higher Aβ protein levels are more susceptible to damage, while protected areas have a less toxic response.
A new study suggests that a breakthrough Alzheimer's treatment could leave millions of people without access to care due to the US healthcare system's limited capacity. The study identifies shortcomings in specialist diagnosis, diagnostic scanners, and infusion centers, and recommends measures to prepare for an Alzheimer's therapy.
A study published in Nature Communications reveals that membralin plays a crucial role in regulating the cell's machinery for producing beta-amyloid, the protein responsible for neuronal death in Alzheimer's disease. The researchers found that membranes with lower levels of this protein are associated with increased neurodegeneration a...
Researchers at Albert Einstein College of Medicine are studying the genetic protections against Alzheimer's disease using two existing longitudinal studies on aging. The study aims to identify networks of genes in healthy centenarians that protect them against dementia, which could help identify new targets for drugs to treat Alzheimer's.